Zacks Investment Research upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a sell rating to a hold rating in a research report sent to investors on Monday morning, Zacks.com reports. The firm currently has $23.00 target price on the stock.
According to Zacks, “In the first quarter of fiscal 2021, strength in Animal Health and Performance Products arms boosted the overall top line for Phirbo. Robust nutritional specialty product and net vaccine sales were impressive. Strong international performance amid the pandemic-led challenging business climate looks impressive. Ongoing business recovery due to strong customer demand looks encouraging. Expansion of both margins raise optimism. A strong balance sheet position is an added plus. On the flip side, dismal show by Phibro's Mineral Nutrition arm in the first quarter of fiscal 2021 is concerning. Lower sales of the Performance Products arm’s copper-based products raise concerns. Foreign exchange fluctuations and stiff competition persist. Phibro has underperformed its industry for the past six months.”
Separately, ValuEngine upgraded Phibro Animal Health from a sell rating to a hold rating in a report on Tuesday, December 1st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $23.80.
PAHC stock opened at $21.14 on Monday. The stock has a 50-day moving average price of $19.28 and a two-hundred day moving average price of $20.01. The stock has a market cap of $855.18 million, a PE ratio of 25.78, a price-to-earnings-growth ratio of 1.56 and a beta of 0.37. The company has a current ratio of 2.87, a quick ratio of 1.62 and a debt-to-equity ratio of 1.96. Phibro Animal Health has a 1 year low of $16.27 and a 1 year high of $29.38.
Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Monday, November 9th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.06. The firm had revenue of $195.20 million during the quarter. Phibro Animal Health had a return on equity of 21.69% and a net margin of 4.19%. On average, analysts forecast that Phibro Animal Health will post 1.15 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Wednesday, December 16th. Investors of record on Wednesday, November 25th were paid a $0.12 dividend. The ex-dividend date was Tuesday, November 24th. This represents a $0.48 annualized dividend and a yield of 2.27%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 44.44%.
A number of large investors have recently modified their holdings of PAHC. Sowell Financial Services LLC lifted its stake in Phibro Animal Health by 24.8% in the 4th quarter. Sowell Financial Services LLC now owns 3,250 shares of the company’s stock valued at $63,000 after purchasing an additional 645 shares during the last quarter. Bank of Montreal Can lifted its position in Phibro Animal Health by 80.2% during the second quarter. Bank of Montreal Can now owns 2,725 shares of the company’s stock worth $67,000 after acquiring an additional 1,213 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in Phibro Animal Health by 211.3% during the third quarter. BNP Paribas Arbitrage SA now owns 5,298 shares of the company’s stock worth $92,000 after acquiring an additional 3,596 shares during the last quarter. Banque Cantonale Vaudoise lifted its position in Phibro Animal Health by 1,531.6% during the third quarter. Banque Cantonale Vaudoise now owns 9,659 shares of the company’s stock worth $168,000 after acquiring an additional 9,067 shares during the last quarter. Finally, Brinker Capital Investments LLC acquired a new stake in Phibro Animal Health during the third quarter worth approximately $208,000.
About Phibro Animal Health
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Read More: Using the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.